TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18501008

Group type: EXPERIMENTAL
Intervention: Individualised activity programme based on goal setting and progression of difficulty of activities delivered by a trained nurse during 8 home visits over 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Time matched home visits to discuss social contacts and networks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individualised activity programme
Number of subjects: 0
Study: 19571079

Group type: EXPERIMENTAL
Intervention: Trabecular Metal tibial component
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cemented tibial component
Number of subjects: 70
Study: 15111668

Group type: EXPERIMENTAL
Intervention: Visual delayed matching‐to‐sample task (DMS48)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patients with mild AD
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patients with moderate AD
Number of subjects: 23

Group type: COMPARATOR
Intervention: Patients with Parkinson disease (PD)
Number of subjects: 23
Study: 11558965

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (healthy adults)
Number of subjects: 7
Study: 15321185

Group type: EXPERIMENTAL
Intervention: Acupressure wristbands
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo wristbands
Number of subjects: 0
Study: 8168348

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg once daily for 3 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Roxithromycin 150 mg twice daily for 7 days
Number of subjects: 60
Study: 3349293

Group type: EXPERIMENTAL
Intervention: R2 gastrectomy
Number of subjects: 43

Group type: COMPARATOR
Intervention: R1 gastrectomy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: R1 and R2 gastrectomy
Number of subjects: 43
Study: 31490862

Group type: EXPERIMENTAL
Intervention: Simulator training
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 145
Study: 28364504

Group type: EXPERIMENTAL
Intervention: Tiagabine 12 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 27440679

Group type: EXPERIMENTAL
Intervention: Mola curry (experimental group)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Rui curry with added retinyl palmitate (positive control group)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Rui curry (negative control group)
Number of subjects: 196
Study: 24866121

Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 40
Study: 22082303

Group type: EXPERIMENTAL
Intervention: Alkalinized lidocaine and heparin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 18
Study: 19708504

Group type: EXPERIMENTAL
Intervention: 131I treatment with oral methyloprednisolone (MP) over 30 days starting at 16 mg/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (18 hyperthyroid patients with no GO symptoms)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 131I treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Studied group
Number of subjects: 21
Study: 17536225

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment adjustment (increase or decrease)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (41 matched patients, treatment unchanged)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Study group (adjusted treatment)
Number of subjects: 59
Study: 15601804

Group type: EXPERIMENTAL
Intervention: Bosentan 31.25 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bosentan 250 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bosentan (all doses)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 20
Study: 11860412

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 g (LAC)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg (LMC)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant patients treated with LAC
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Clarithromycin-resistant patients treated with LMC
Number of subjects: 228
Study: 10453438

Group type: EXPERIMENTAL
Intervention: Low-fat diet (15% of energy from fat, maintenance of energy intake)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Low-energy diet (25% energy reduction)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Combination low fat and low energy diet
Number of subjects: 113

Group type: COMPARATOR
Intervention: Nonintervention diet
Number of subjects: 113
Study: 8552463

Group type: EXPERIMENTAL
Intervention: Drawing on a da Vinci window (vertical glass pane)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drawing on paper (flat on the table)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trapezoid model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tilted rectangle model
Number of subjects: 0
Study: 2216204

Group type: EXPERIMENTAL
Intervention: 0.5 mg prostaglandin E2 gel intracervically (N = 52)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 3 mg prostaglandin E2 gel intravaginally (N = 48)
Number of subjects: 100
Study: 350861

Group type: EXPERIMENTAL
Intervention: Penfluridol (administered once weekly)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Trifluoperazine (administered daily)
Number of subjects: 25
Study: 30905729

Group type: EXPERIMENTAL
Intervention: Stent-in-stent (SIS)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Stent-by-stent (SBS)
Number of subjects: 69
Study: 28235027

Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E gp120 alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALVAC-HIV alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of ALVAC-HIV and AIDSVAX B/E gp120
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 25468399

Group type: EXPERIMENTAL
Intervention: Guided deep breathing group (GDBG)
Number of subjects: 150

Group type: COMPARATOR
Intervention: All groups (including GDBG, MLG, SSG)
Number of subjects: 150
Study: 24131602

Group type: EXPERIMENTAL
Intervention: Widex SoundTracker
Number of subjects: 20

Group type: COMPARATOR
Intervention: Real-ear analyzers (Verifit and 6500)
Number of subjects: 20
Study: 21829664

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 669

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 669
Study: 19561524

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program (1 year duration, including respiratory reeducation training and muscular training)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home-based pulmonary rehabilitation program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 17413093

Group type: EXPERIMENTAL
Intervention: Soymilk diet (37.5 g/d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Animal protein diet
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Soyflour diet
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole soybean diet
Number of subjects: 28
Study: 15197520

Group type: EXPERIMENTAL
Intervention: Intravenous desmopressin (2 microg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oral desmopressin (0.2 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Daytime intravenous desmopressin (2 microg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Daytime oral desmopressin (0.2 mg)
Number of subjects: 15
Study: 11317951

Group type: EXPERIMENTAL
Intervention: Multi-Sensory Stimulation (MSS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Activity sessions (Control)
Number of subjects: 50
Study: 9569997

Group type: EXPERIMENTAL
Intervention: Avitriptan 50 mg under fasting conditions
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Avitriptan 50 mg after a high-fat breakfast
Number of subjects: 24
Study: 7914751

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6-MP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfasalazine (SASP)
Number of subjects: 0
Study: 3073524

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily for up to 12 weeks)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo (1 g four times daily for up to 12 weeks)
Number of subjects: 138
Study: 31689329

Group type: EXPERIMENTAL
Intervention: Healthy School Start II (HSS II) intervention
Number of subjects: 24
Study: 28245243

Group type: EXPERIMENTAL
Intervention: Serelaxin intravenous infusion (80 μg/kg/d for 60 min, then 30 μg/kg/d for 60 min)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Terlipressin (single 2-mg i.v. bolus)
Number of subjects: 40
Study: 25409324

Group type: EXPERIMENTAL
Intervention: Nighttime feeding of casein (CAS)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nighttime feeding of whey (WH)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nighttime feeding of carbohydrate (CHO)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Exercise training (2 days of resistance training and 1 day of high-intensity interval training)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nighttime feeding of CAS combined with exercise training
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Nighttime feeding for 4 weeks combined with exercise training
Number of subjects: 37
Study: 23509083

Group type: EXPERIMENTAL
Intervention: Homologous platelet gel (PG)
Number of subjects: 21
Study: 21462008

Group type: EXPERIMENTAL
Intervention: Reading intervention
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study: 19796051

Group type: EXPERIMENTAL
Intervention: Sildenafil (25, 50, or 100 mg)
Number of subjects: 841

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841
Study: 16881776

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Exposure group therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Exposure therapy
Number of subjects: 107
Study: 15058150

Group type: EXPERIMENTAL
Intervention: Statins for primary prevention (patients with hypercholesterolemia but no known CHD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statins for secondary prevention (patients with known CHD)
Number of subjects: 0
Study: 11353547

Group type: EXPERIMENTAL
Intervention: High-frequency flow interruption ventilation (HFFI)
Number of subjects: 36
Study: 9602198

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide 1 mg every 12 hours for 5 days, then 500 micrograms every 12 hours for a total of 6 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nebulized placebo (0.9% saline) for 6 weeks
Number of subjects: 40
Study: 7973480

Group type: EXPERIMENTAL
Intervention: Active laser (GA-AL-AS 30 mW/830 nm low power laser)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 2537699

Group type: EXPERIMENTAL
Intervention: 2 or 5 mg benazepril hydrochloride
Number of subjects: 26
Study: 4909817

Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium capsules (50 mg, four times a day for 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (capsule identical in every respect except that it did not contain carbenoxolone)
Number of subjects: 100
Study: 31984682

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) at 10 Hz in ANTHEM-HF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vagus nerve stimulation (VNS) in NECTAR-HF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vagus nerve stimulation (VNS) in INOVATE-HF
Number of subjects: 0
Study: 30821139

Group type: EXPERIMENTAL
Intervention: AF1q gene polymorphism detection using PCR-RFLP
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proteomic analysis using iTraq
Number of subjects: 40
Study: 28110812

Group type: EXPERIMENTAL
Intervention: Omega-3 group (n = 25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo group (n = 24)
Number of subjects: 49
Study: 26052147

Group type: EXPERIMENTAL
Intervention: 1.6 g Beta-Alanine (BA) + 34 g dextrose
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (34 g dextrose)
Number of subjects: 12
Study: 23719347

Group type: EXPERIMENTAL
Intervention: Prophylactic infant cotrimoxazole
Number of subjects: 2369

Group type: COMPARATOR
Intervention: No extended antiretroviral prophylaxis
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Low birth weight (2000-2499 g)
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Rainy season
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Low infant WBC count at birth
Number of subjects: 2369
Study: 21709060

Group type: EXPERIMENTAL
Intervention: m-SVG
Number of subjects: 3014

Group type: COMPARATOR
Intervention: s-SVG
Number of subjects: 3014
Study: 19536128

Group type: EXPERIMENTAL
Intervention: Tadalafil (5 mg once daily)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 17074270

Group type: EXPERIMENTAL
Intervention: Individual ventilation (IV) group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Lower‐tidal‐volume (LTV) group
Number of subjects: 30
Study: 16295054

Group type: EXPERIMENTAL
Intervention: Pulsating electrostatic field (PESF) therapy, 30 min daily exposure, adjusted between 2 and 9 kV
Number of subjects: 14
Study: 15332347

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg/day upon awakening
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg/day at bedtime
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Doxazosin GITS 4 mg/day at bedtime (polytherapy)
Number of subjects: 91
Study: 10742313

Group type: EXPERIMENTAL
Intervention: Infection control intervention (training of child care staff about transmission of infection, handwashing, and aseptic nosewiping technique)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 311
Study: 8932265

Group type: EXPERIMENTAL
Intervention: Donor livers with up to 30% fatty infiltration
Number of subjects: 59
Study: 1402213

Group type: EXPERIMENTAL
Intervention: Indobufen (INB) 400 mg daily
Number of subjects: 113

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 900 mg daily plus dipyridamole (DP) 225 mg daily
Number of subjects: 113
Study: 3919790

Group type: COMPARATOR
Intervention: 26% oxygen breathing
Number of subjects: 14
Study: 2975582

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol + 75 micrograms gestodene
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol + 150 micrograms desogestrel
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 11
Study: 29286989

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy-based stress management program for 10 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28790966

Group type: EXPERIMENTAL
Intervention: Online synchronous Internet streaming classroom using the Adobe Connect e‐learning platform
Number of subjects: 274

Group type: COMPARATOR
Intervention: Traditional classroom
Number of subjects: 274
Study: 26137881

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day)
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) in rash subgroup
Number of subjects: 670

Group type: COMPARATOR
Intervention: Best supportive care (placebo)
Number of subjects: 670
Study: 23811987

Group type: EXPERIMENTAL
Intervention: Desmopressin orally disintegrating tablet (ODT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intranasal desmopressin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Desmopressin ODT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intranasal desmopressin to desmopressin ODT
Number of subjects: 20
Study: 21692282

Group type: EXPERIMENTAL
Intervention: Acupuncture plus herbal medicine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Chinese herbal medicine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 160

Group type: COMPARATOR
Intervention: Glycerine Enema
Number of subjects: 160
Study: 19930678

Group type: EXPERIMENTAL
Intervention: Smoke-free legislation in Wales implemented in April 2007
Number of subjects: 1750

Group type: EXPERIMENTAL
Intervention: Smoke-free legislation in Wales
Number of subjects: 1750
Study: 17074342

Group type: EXPERIMENTAL
Intervention: Histologic assessment of the luteal phase endometrium using Noyes criteria and immunohistochemical analysis for expression of inhibin, activin, and follistatin subunits
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Doppler analysis for perifollicular and endometrial blood flow
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Serum concentrations of E(2), LH, FSH, P, and inhibin B at the time of LH surge and at LH +7 days
Number of subjects: 43
Study: 15193852

Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Start Program) with > or =75% of visits called for in the model
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Home visiting program (Healthy Start Program)
Number of subjects: 643
Study: 11681532

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sequential methotrexate and 5-fluorouracil
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: CA 15-3
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TPS
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: TPA and TPS
Number of subjects: 57
Study: 9779028

Group type: EXPERIMENTAL
Intervention: Enoxaparin 1 mg/kg every 12 h subcutaneously
Number of subjects: 3171

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) as a continuous intravenous infusion
Number of subjects: 3171
Study: 7830861

Group type: EXPERIMENTAL
Intervention: Ultrafiltered dialysate
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standard bicarbonate dialysate
Number of subjects: 11
Study: 3418366

Group type: EXPERIMENTAL
Intervention: Adult Day Hospital (ADH)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 442
Study: 30391995

Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli; 0.8 ng/kg of body weight)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 115
Study: 27385478

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 73
Study: 25359424

Group type: EXPERIMENTAL
Intervention: Oral T3 treatment (20 μg per day for 3 months)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 22819624

Group type: EXPERIMENTAL
Intervention: 0.25 mg clonazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.03 mg clonazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term memory testing 4 h after reactivation
Number of subjects: 0
Study: 21992076

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.45%
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Amfenac (active metabolite of nepafenac)
Number of subjects: 122
Study: 19130899

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Healthy adults
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with idiopathic Parkinson's disease
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (subjective vs objective cognition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (mood vs objective cognitive performance)
Number of subjects: 0
Study: 17547048

Group type: EXPERIMENTAL
Intervention: Regimen-1: albendazole 800 mg/day twice daily for 3 consecutive days
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Regimen-2: albendazole 800 mg/day twice daily for 5 consecutive days
Number of subjects: 115

Group type: COMPARATOR
Intervention: Regimen-1
Number of subjects: 115

Group type: COMPARATOR
Intervention: Regimen-2
Number of subjects: 115
Study: 15385655

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14527

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14527

Group type: EXPERIMENTAL
Intervention: Both captopril and valsartan
Number of subjects: 14527

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 14527
Study: 11687509

Group type: EXPERIMENTAL
Intervention: Low-glycogen trial
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control trial
Number of subjects: 6
Study: 9405962

Group type: EXPERIMENTAL
Intervention: Tianeptine (12.5 mg t.i.d)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 342
Study: 8199696

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (600 mg/day)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/day) and Ursodeoxycholic acid (600 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (neither drug)
Number of subjects: 41
Study: 3649524

Group type: EXPERIMENTAL
Intervention: Learning sessions to promote autonomy (6 sessions, 1 hour each)
Number of subjects: 92
Study: 31173870

Group type: EXPERIMENTAL
Intervention: Yogliptin 2.5-600 mg
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Yogliptin 25-400 mg
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Yogliptin 400 mg
Number of subjects: 104
Study: 28401843

Group type: EXPERIMENTAL
Intervention: Circle of Security-Parenting Intervention (COS-P)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 141
Study: 25779953

Group type: EXPERIMENTAL
Intervention: Tigatuzumab (TIG) with nab-paclitaxel (nab-PAC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: nab-paclitaxel (nab-PAC)
Number of subjects: 64